Healwell AI (AIDX) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenue of CAD 13.7 million, up 738% year-over-year, driven by acquisitions and increased pharma partner activity.

• Completed four rounds of financing totaling nearly CAD 50 million and four acquisitions, expanding reach and capabilities in healthcare AI and data science.

• Developed and launched four AI copilots for disease detection, doubling signed master service agreements (MSAs) with life sciences companies year-over-year.

• Positioned as an end-to-end partner for the pharmaceutical industry, integrating AI with CRO capabilities.

• Accelerated commercialization of AI-enabled patient identification and healthcare data solutions across public and private sectors.

Financial highlights

• Q3 2024 revenue reached CAD 13.7 million, up from CAD 1.6 million in Q3 2023, primarily due to acquisitions.

• Adjusted gross profit was CAD 5.9 million, compared to CAD 300,000 in Q3 2023; gross margin improved to 43% from 20% year-over-year.

• Adjusted EBITDA loss was CAD 3.4 million, versus a loss of CAD 2.5 million in Q3 2023; net loss was CAD 11.1 million, up from CAD 6.6 million.

• Ended Q3 with CAD 15.2 million in cash, down from CAD 19.2 million at December 31, 2023, mainly due to acquisitions.

• Weighted average shares outstanding: 162.7 million; net loss per share: $(0.06).

Outlook and guidance

• Targeting an annualized revenue run rate approaching CAD 100 million by year-end, with profitability on an Adjusted EBITDA basis expected in 2025.

• Q4 revenue expected to be incrementally higher than Q3, though BioPharma's Q4 revenue may be lower than previously forecast due to industry volatility.

• Management expects further M&A announcements by year-end, with a robust acquisition pipeline.

• Strategic focus on M&A, new commercialization agreements, organic growth, and expanding CRO capabilities.